ERBB2 and neoplasm: Findings suggest that expression levels of HER2 might vary within a single tumor focus (intratumoral heterogeneity) as well as between different tumor foci and between the primary tumor(s) and synchronous axillary lymph node metastases (intertumoral heterogeneity) (3–5).